Disulfidptosis in head and neck squamous carcinoma: Integrative bioinformatic and in‐vitro analysis
Oral Diseases · 2024
DOI: 10.1111/odi.14977 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2024. Verfasst von Xufeng Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Dentistry, University of Debrecen, Debrecen, Hungary. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Computational Biology, Tumor Microenvironment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Seed Foundation of the Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Head and neck squamous carcinoma (HNSC) is a prevalent global malignancy with limited treatment options, which necessitates the development of novel therapeutic strategies. Disulfidptosis, a recently discovered and unique cell death pathway, may offer promise as a treatment target in HNSC. Materials and Methods We identified disulfidptosis‐related genes (DRGs) using multiple algorithms and developed a prognostic model based on a disulfidptosis‐related gene index (DRGI). The model's predictive accuracy was assessed by ROC‐AUC, and patients were stratified by risk scores. We investigated the tumor immune microenvironment, immune responses, tumorigenesis pathways, and chemotherapy sensitivity (IC50). We also constructed a diagnostic model using 20 machine‐learning algorithms and validated PCBP2 expression through RT‐qPCR and western blot.
Results
We developed a 12‐DRG DRGI prognostic model, classifying patients into high‐ and low‐risk groups, with the high‐risk group experiencing poorer clinical outcomes. Notable differences in tumor immune microenvironment and chemosensitivity were observed, with reduced immune activity and suboptimal treatment responses in the high‐risk group. Advanced machine learning and in‐vitro experiments supported DRGI's potential as a reliable HNSC diagnostic biomarker.
Conclusion
We established a novel DRGI‐based prognostic and diagnostic model for HNSC, exploring its tumor immune microenvironment implications, and offering valuable insights for future research and clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Dentistry, University of Debrecen, Debrecen, Hungary.
- School of Stomatology, Southwest Medical University, Luzhou, China.
- Department of Gastroenterology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, China.
- Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- College of Stomatology, Shanghai Jiao Tong University, Shanghai, China.
- National Center for Stomatology, Shanghai, China.
ORCID-Profile: Xufeng Huang, Rao Fu, Zhengrui Li, Ling Zhang
Förderung
- Seed Foundation of the Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
- National Natural Science Foundation of China
Zitieren
APA
Huang, X., Yang, J., Wang, Q., Fu, R., Wen, X., Li, Z., & Zhang, L. (2024). Disulfidptosis in head and neck squamous carcinoma: Integrative bioinformatic and in‐vitro analysis. Oral Diseases. https://doi.org/10.1111/odi.14977
Vancouver
Huang X, Yang J, Wang Q, Fu R, Wen X, Li Z, et al. Disulfidptosis in head and neck squamous carcinoma: Integrative bioinformatic and in‐vitro analysis. Oral Diseases. 2024. doi:10.1111/odi.14977
BibTeX
@article{Huang2024,
author = {Huang, Xufeng and Yang, Jinyan and Wang, Qi and Fu, Rao and Wen, Xutao and Li, Zhengrui and Zhang, Ling},
title = {Disulfidptosis in head and neck squamous carcinoma: Integrative bioinformatic and in‐vitro analysis},
journal = {Oral Diseases},
year = {2024},
doi = {10.1111/odi.14977}
}
EUVIMED